Mr Mrs Miss Ms Dr Other

Dr
Laurence
Gainey

Partner & Patent Attorney

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 778 545 8684
Email. [email protected]

Experience

Laurence is a highly-experienced European and UK qualified patent attorney with over 25 years’ experience handling pharmaceutical and biotechnology subject matter. He has successfully managed patent portfolios on a variety of biotechnology subject matter, including diagnostic tools and targets, personalised healthcare (PHC), antisense oligonucleotide molecules, peptide and antibody (e.g. polyclonal, monoclonal, bispecific and conjugated) therapeutics, as well as handling the IP for small molecule discovery and high profile on sale pharmaceutical products, some with greater than $1bn annual sales.

After gaining a PhD in molecular biology from Reading University, Laurence joined a small biotechnology company to work in the laboratory on virus-based antigen delivery systems. After a couple of years, he moved internally to train as a patent attorney. In the same year as qualifying as European patent attorney Laurence joined the in-house patent department of AstraZeneca Pharmaceutical Ltd. where he worked for over 18 years before joining HGF’s Manchester office as a Patent Director in September 2017.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Cell and Molecular Biology

PHD

Molecular Biology - Reading University

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law - Queen Mary University of London

Publications

MBL Webinar entitled "Patent Due Diligence - The Fundamental Portfolio Checks Required"

View publication online

Chapter "Patent Considerations When Embarking on New Antisense Drug Programs" for the Open Access book "Antisense RNA Design, Delivery, and Analysis". "

View publication online

Related News

New Blog Series: IP Ingredients, Part 1: Can you patent a recipe?

A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted.  To many …

Read article

UPC and Forum Shopping – Rule 17.3

Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …

Read article
Event - 16th November 2023

Webinar in cooperation with the BVIZ: Licensing and Technology Transfer

HGF is pleased to invite you to our upcoming German-language webinar in cooperation with the BVIZ on “In- and Out-licensing of Technologies” on 16th of November 2023. The webinar will …

Event details

Investing in Patents for Space Tech: Safeguarding Innovations in the Space Sector

The advent of commercial launch capabilities has opened up space as a unique frontier for innovation. However, in space, any acts of patent infringement almost always go unseen. Thus, it’s …

Read article

End of EPO "10 day rule" from 1 November 2023 – 4 weeks to go

Any communications sent from the EPO on or after 1 November 2023 will no longer have the “ten day rule” applied to them.   This means that communications are deemed to …

Read article
Event - 21st, 28th November 2023

Dresden & Salzburg Seminar: Licensing and Technology Transfer

HGF is pleased to invite you to our upcoming German-language seminar on “In- and Out-licensing of Technologies” in Salzburg and Dresden. The seminar will offer you the opportunity to gain …

Event details
Event - 26th September 2023

Bioforward OBN Conference 2023

Bioforward, OBN’s ‘Roadmap for Growth’ Life Sciences event is set to take place at The King’s Centre in Oxford on Tuesday 26th September 2023. This event is designed to provide the support, skills, know-how …

Event details

AI-Powered Personalised Medicine

The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.